You are here

Bangladesh company offering cheap copy of Gilead's blockbuster hep C drug

In the US, Sovaldi has sparked a backlash from commercial health insurers because of its cost of US$84,000 for a 12-week course of treatment.


A US$10 version of Sovaldi, the Gilead Sciences Inc hepatitis C treatment that sells for US$1,000 a pill in the US, is now available in Bangladesh and could make its way to other parts of the world where the US company doesn't have patents.

Incepta Pharmaceuticals Ltd doesn'